[Form 4] Voyager Therapeutics, Inc. Insider Trading Activity

Rhea-AI Filing Summary

Toby Ferguson, Chief Medical Officer of Voyager Therapeutics, Inc. (VYGR), reported the sale of 19,000 shares of the issuer's common stock on 08/18/2025 at a weighted average price of $3.73 per share. After the reported sale, Mr. Ferguson beneficially owned 138,914 shares, held directly. The filing discloses that the $3.73 figure is a weighted average for multiple transactions executed at prices ranging from $3.69 to $3.79 and states the reporting person will provide a detailed breakdown of shares sold at each price on request. The Form 4 was signed by an attorney-in-fact on 08/20/2025.

Positive

• Transaction fully disclosed on Form 4 with transaction date, weighted average price and post-sale ownership provided
• Price range disclosed (sales executed between $3.69 and $3.79) and reporting person offers to provide per-trade details on request
• No derivative activity reported in Table II

Negative

• Insider sold 19,000 shares, reducing direct beneficial ownership to 138,914 shares
• Form 4 provides no context about the reason for the sale or use of proceeds

Insights

Corporate Governance Expert

TL;DR: Insider sale disclosed on Form 4; ownership remains material but reduced by 19,000 shares.

The filing documents a routine Section 16 disclosure of an insider sale by the Chief Medical Officer. The report specifies the exact number of shares sold, the weighted average price and the remaining beneficial ownership, and includes a note on the price range with an offer to provide per-trade detail. There are no derivative transactions reported. From a governance perspective, the document meets Form 4 disclosure requirements and preserves traceability of insider trades.

Securities Analyst

TL;DR: A 19,000-share disposition at ~$3.73 reduces insider stake to 138,914 shares; no exercise or derivative activity noted.

The sale occurred 08/18/2025 across multiple executions at $3.69–$3.79, producing a weighted average of $3.73. The filing clearly states the post-transaction direct beneficial ownership. There is no information in this Form 4 about any company-specific catalysts or proceeds usage. The disclosure is transaction-specific and does not provide further financial context.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Ferguson Toby

(Last) (First) (Middle)

C/O VOYAGER THERAPEUTICS, INC.

75 HAYDEN AVENUE

(Street)

LEXINGTON MA 02421

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Voyager Therapeutics, Inc. [ VYGR ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Medical Officer

3. Date of Earliest Transaction (Month/Day/Year)
08/18/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	08/18/2025		S		19,000	D	$3.73(1)	138,914	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.69 to $3.79, inclusive. The reporting person undertakes to provide to Voyager Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (1) to this Form 4.

	/s/ Robin Swartz, as Attorney-in-Fact for Toby Ferguson	08/20/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did Voyager Therapeutics (VYGR) insider Toby Ferguson report on Form 4?

The Form 4 reports that Toby Ferguson sold 19,000 shares of common stock on 08/18/2025 at a weighted average price of $3.73 per share.

How many Voyager shares does Toby Ferguson own after the reported sale?

After the sale, the filing shows Mr. Ferguson beneficially owned 138,914 shares, held directly.

At what prices were the shares sold in the VYGR Form 4?

The filing states sales occurred at prices ranging from $3.69 to $3.79, and the reported $3.73 is a weighted average.

Does the Form 4 show any options, warrants, or other derivatives for Toby Ferguson?

No. Table II contains no derivative transactions reported in this Form 4.

When was the Form 4 signed and by whom?

The Form 4 was signed on behalf of Toby Ferguson by Robin Swartz, as Attorney-in-Fact, on 08/20/2025.